Skip to main content
Home > Week in Review > Offerings

Chronological Index of : Financial News

 Current Issue
  • AveXis amends IPO

    AveXis Inc., Bannockburn, Ill. Business: Neurology Date announced: 2016-02-01 Type: IPO To be raised: Up to $89.3 million Shares: 4.3 million Price: $19-$21 Underwriters: Goldman Sachs; Jefferies; BMO Capital Markets; …

    Published on 2/8/2016
  • Cancer Prevention Pharmaceuticals amends IPO

    Cancer Prevention Pharmaceuticals Inc., Tucson, Ariz. Business: Cancer Date announced: 2016-02-02 Type: IPO To be raised: Up to $26.9 million Shares: 1.9 million Price: $12-$14 Underwriters: Aegis Capital; Maxim Group …

    Published on 2/8/2016
  • Proteostasis amends IPO

    Proteostasis Therapeutics Inc., Cambridge, Mass. Business: Pulmonary, Endocrine/Metabolic, Neurology Date announced: 2016-02-01 Type: IPO To be raised: Up to $53.9 million Shares: 3.9 million Price: $12-$14 Underwriters…

    Published on 2/8/2016
  • TiGenix amends follow-on

    TiGenix N.V. (Euronext:TIG), Leuven, Belgium Business: Musculoskeletal, Gene/Cell therapy Date announced: 2016-02-03 Type: Follow-on To be raised: TBD Shares: TBD Price prior: EUR0.99 Underwriters: Canaccord; Nomura; …

    Published on 2/8/2016
  • Acelity completes venture financing

    Acelity L.P. Inc., San Antonio, Texas Business: Dermatology Date completed: 2016-02-02 Type: Venture financing Raised: $400 million Investor: Institutional investors Note: The financing comprises senior secured notes, …

    Published on 2/8/2016
  • Atomo Diagnostics completes venture financing

    Atomo Diagnostics, Leichhardt, Australia Business: Diagnostic Date completed: 2016-02-01 Type: Venture financing Raised: $6 million Investor: Global Health Investment Fund Note: The financing is a loan.

    Published on 2/8/2016
  • BeiGene completes IPO

    BeiGene Ltd. (NASDAQ:BGNE), Beijing, China Business: Cancer, Autoimmune Date completed: 2016-02-02 Type: IPO Raised: $158.4 million Shares: 6.6 million Price: $24 Shares after offering: 31.5 million Underwriters: …

    Published on 2/8/2016
  • BioDirection completes venture financing

    BioDirection Inc., Tucson, Ariz. Business: Diagnostic Date completed: 2016-02-03 Type: Venture financing Raised: $4 million Investors: Provident Healthcare Capital; and other undisclosed investors Note: The company …

    Published on 2/8/2016
  • Cellular Biomedicine completes private placement

    Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Business: Gene/Cell therapy Date completed: 2016-02-04 Type: Private placement Raised: $5 million Shares: 263,158 Price: $19 Shares after offering: 11.9 …

    Published on 2/8/2016
  • Editas Medicine completes IPO

    Editas Medicine Inc. (NASDAQ:EDIT), Cambridge, Mass. Business: Gene/Cell therapy, Genomics Date completed: 2016-02-02 Type: IPO Raised: $94.4 million Shares: 5.9 million Price: $16 Shares after offering: 35.7 million …

    Published on 2/8/2016
  • Enyo Pharma completes venture financing

    Enyo Pharma S.A.S., Lyon, France Business: Infectious Date completed: 2016-02-03 Type: Venture financing Raised: EUR6 million ($6.5 million) Investors: Sofinnova Partners; Morningside Group; InnoBio Fund Note: Enyo …

    Published on 2/8/2016
  • ImmuPharma completes placing

    ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Placing Raised: L3.9 million ($5.5 million) Shares: 14.9 million Price: 26p Shares after offering: 121.…

    Published on 2/8/2016
  • ImmuPharma completes private placement

    ImmuPharma plc (LSE:IMM), London, U.K. Business: Autoimmune, Neurology, Infectious Date completed: 2016-02-05 Type: Private placement Raised: L4.4 million ($6.3 million) Shares: 17.9 million Price: 26p Shares after …

    Published on 2/8/2016
  • KemPharm completes private placement of senior convertible notes

    KemPharm Inc. (NASDAQ:KMPH), Coralville, Iowa Business: Neurology Date completed: 2016-02-04 Type: Private placement of senior convertible notes Raised: $75 million Shares outstanding prior: 14.5 million Investor: …

    Published on 2/8/2016
  • LAM Therapeutics completes venture financing

    LAM Therapeutics, Guilford, Conn. Business: Pulmonary, Cancer Date completed: 2016-02-03 Type: Venture financing Raised: $40 million

    Published on 2/8/2016
  • Mission Therapeutics completes venture financing

    Mission Therapeutics Ltd., Cambridge, U.K. Business: Cancer, Neurology Date completed: 2016-02-02 Type: Venture financing Raised: L60 million ($85.7 million) Investors: Imperial Innovations Group plc; Woodford …

    Published on 2/8/2016
  • Modulate Therapeutics completes venture financing

    Modulate Therapeutics Inc., Montreal, Quebec Business: Cancer Date completed: 2016-02-01 Type: Venture financing Raised: $16.5 million Investor: TVM Life Science Ventures

    Published on 2/8/2016
  • Morphogen-IX completes venture financing

    Morphogen-IX Ltd., Babraham, U.K. Business: Cardiovascular Date completed: 2016-01-18 Type: Venture financing Raised: L1.5 million ($2.1 million) Investors: Index Ventures; Cambridge Innovation Capital plc; Cambridge …

    Published on 2/8/2016
  • Nymox completes private placement

    Nymox Pharmaceutical Corp. (NASDAQ:NYMX), Saint-Laurent, Quebec Business: Genitourinary, Neurology, Diagnostic Date completed: 2016-02-04 Type: Private placement Raised: $2.1 million Price: $2 Shares outstanding prior: …

    Published on 2/8/2016
  • OptiBiotix Health completes placing

    OptiBiotix Health plc (LSE:OPTI), York, U.K. Business: Endocrine/Metabolic Date completed: 2016-02-05 Type: Placing Raised: L1 million ($1.4 million) Shares: 1.3 million Price: 78p Shares after offering: 77.6 million …

    Published on 2/8/2016
  • Pacgen completes private placement of units

    Pacgen Life Science Corp. (TSX-V:PBS), Vancouver, B.C. Business: Infectious, Pulmonary, Supply/Service Date completed: 2016-02-03 Type: Private placement of units Raised: C$318,000 ($226,702) Units: 5.3 million Price: C…

    Published on 2/8/2016
  • Spero Therapeutics completes venture financing

    Spero Therapeutics LLC, Cambridge, Mass. Business: Infectious Date completed: 2016-02-02 Type: Venture financing Raised: Not disclosed Investors: Atlas Venture; SR One; Merck Research Labs Ventures Fund; Lundbeckfond …

    Published on 2/8/2016
  • Tivorsan completes venture financing

    Tivorsan Pharmaceuticals Inc., Providence, R.I. Business: Musculoskeletal, Neurology Date completed: 2016-02-05 Type: Venture financing Raised: $1.8 million Placement agent: T.R. Winston Investors: Institutional …

    Published on 2/8/2016
  • Unity Biotechnology completes venture financing

    Unity Biotechnology, San Francisco, Calif. Business: Autoimmune, Ophthalmic, Cardiovascular Date completed: 2016-02-03 Type: Venture financing Raised: Not disclosed Investors: Arch Venture Partners; Venrock; WuXi …

    Published on 2/8/2016
  • Agile Therapeutics financial update

    Agile Therapeutics Inc. (NASDAQ:AGRX), Princeton, N.J. Business: Genitourinary, Endocrine/Metabolic Date announced: 2016-02-04 Note: Agile Therapeutics raised $5.2 million through the sale of 826,771 shares at $6.35 to …

    Published on 2/8/2016

< Previous   1  2  3  4  5  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993